Clinical Trials Update: Dec. 18, 2006
Non-Small Cell Lung Cancer Prostate Cancer Parkinson's Disease
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
Non-Small Cell Lung Cancer
The purpose of this study is to compare the effect and safety of an investigational drug with pemetrexed in the second or third line treatment of advanced non-small cell lung cancer.
Successful candidates for this study should be 18-years-old or older who have been diagnosed with non-small cell lung cancer, previously received one or two chemotherapeutic treatments, and have not had previous therapy with EGFR inhibitor, MEK inhibitor or pemetrexed or any recent surgery.
The research sites are in Ann Arbor, Mich., Nashville, Tenn., and New York City.
DN-101, a high dose of calcitriol, which is found in Vitamin D, will be evaluated for effectiveness in prolonging patient survival rates in people with androgen-independent prostate cancer.
Volunteers may not have had any prior chemotherapy treatment with Docetaxel.
The research site is in Gainesville, Fla.
This is a clinical research study evaluating the safety and effectiveness of a test drug for the treatment of Parkinson's disease.
Eligible candidates must be at least 30 years old who have been diagnosed with Idiopathic Parkinson's disease.
The research site is in Phoenix, Ariz.
Copyright 2006 Thomson CenterWatch. All rights reserved.